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Objective
Cryopyrin-associated periodic syndrome (CAPS) is a
heterogeneous group of diseases characterized by exces-
sive Interleukin-1b (IL-1 b) release resulting in severe
systemic and organ inflammation. Canakinumab targets
IL-1b and is approved at standard dose for children and
adults with all CAPS phenotypes. Limited data are avail-
able regarding real-life effectiveness of canakinumab in
patients living with CAPS. Therefore the aim of the
study was to evaluate the real-life dosing practice and
effectiveness of canakinumab in CAPS.
Methods
A multi-center study of consecutive children and adults
with CAPS treated with canakinumab was performed.
Demographics, CAPS phenotype and disease activity,
inflammatory markers and canakinumab treatment strat-
egy were recorded. Treatment response was assessed
using CAPS disease activity scores, CRP and/or SAA
levels. Comparisons between age groups, CAPS pheno-
types and centers were conducted.
Results
A total of 68 CAPS patients at nine centers were
included, these were 31 males and 37 females; median
age was 25 years and 27 (40%) were children. All CAPS
phenotypes were represented. Median follow up was
28 months. Overall, complete response (CR) was seen in
72% of CAPS patients, significantly less often in severe
(14%) than in mild CAPS phenotypes (79%). Only 53%
attained CR on standard dose. Dose increase was more
commonly required in children (56%) than in adults
(22%). Centers with treat-to-target approach achieved
significantly higher CR rates (94% vs 50%).
Conclusion
Real-life effectiveness of canakinumab in CAPS was sig-
nificantly lower than in controlled trials. Treat-to-target
strategies may improve the outcome of children and
adults living with CAPS.
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